Challenge:

A European investor was evaluating four potential investments spanning distinct technologies and therapeutic areas: a theranostic agent, a DNA damage response inhibitor, a virus-like drug conjugate targeting solid tumors, and a biologic targeting iron metabolism for genetic diseases. Before committing to full due diligence on any of them, they needed an efficient comparative assessment to identify the strongest opportunities and surface any early red flags.

Solution:

Each asset required different scientific expertise to evaluate properly. The theranostic involved both imaging and therapeutic assessment. The DDR inhibitor sat in a competitive landscape with multiple approved and late-stage agents requiring careful differentiation analysis. The virus-like drug conjugate represented a newer modality with limited clinical precedent. The iron metabolism biologic raised orphan development and regulatory pathway considerations.

We assembled consultants with relevant expertise for each technology and conducted separate triage-level assessments. Each assessment addressed the same core questions:

• Is the target robust?
• Have others addressed the same target, and if so, what can be learned?
• How differentiated is the asset?
• What's the strength of the data so far?
• Is the trial design appropriate?
• Is the commercial opportunity real and substantive?
• What's the competitive position and implications for value?

Applying a consistent framework across four very different assets allowed us to present comparative findings -- ranking the opportunities by scientific risk, commercial potential, and overall investment attractiveness -- rather than four isolated assessments.

Due Diligence Consulting

Alacrita has conducted due diligence for pharma, biotech, investors, and academia since 2011. For portfolio triage and investor DD, we assemble consultants with expertise matched to each asset's specific technology and therapeutic area, enabling comparative assessment across diverse opportunities.